$CUE
Cue Biopharma Inc

2022 Q2 Form 10-Q Financial Statement

#000095017022008990 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q1
Revenue $26.00K $1.000M $1.553M
YoY Change -99.05% -35.61% 72.56%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.782M $5.156M $4.230M
YoY Change -11.12% 21.89% 6.55%
% of Gross Profit
Research & Development $9.592M $10.08M $9.816M
YoY Change 9.47% 2.71% -0.91%
% of Gross Profit
Depreciation & Amortization $212.0K $220.0K $218.0K
YoY Change -8.23% 0.92% 12.37%
% of Gross Profit
Operating Expenses $13.12M $15.24M $14.07M
YoY Change 0.57% 8.29% 1.27%
Operating Profit -$13.09M -$14.24M -$12.52M
YoY Change 27.05% 13.74% -3.67%
Interest Expense $206.0K $25.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$118.0K -$17.00K $13.00K
YoY Change -591.67% -230.77% -92.66%
Pretax Income -$13.21M -$14.26M -$12.51M
YoY Change 28.49% 13.95% -2.42%
Income Tax
% Of Pretax Income
Net Earnings -$13.21M -$14.26M -$12.51M
YoY Change 28.49% 13.99% -2.44%
Net Earnings / Revenue -50800.0% -1425.5% -805.22%
Basic Earnings Per Share -$0.37 -$0.44
Diluted Earnings Per Share -$373.6K -$436.8K -$411.1K
COMMON SHARES
Basic Shares Outstanding 35.37M 33.01M
Diluted Shares Outstanding 35.36M 32.64M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $66.13M $67.93M $73.30M
YoY Change -10.54% -7.33% 50.42%
Cash & Equivalents $66.13M $67.93M $73.41M
Short-Term Investments $0.00 $0.00 $0.00
Other Short-Term Assets $2.142M $7.095M $2.700M
YoY Change -44.41% 162.78% 42.11%
Inventory
Prepaid Expenses
Receivables $736.0K $925.0K $1.400M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $69.00M $75.95M $77.40M
YoY Change -13.4% -1.88% 51.2%
LONG-TERM ASSETS
Property, Plant & Equipment $1.765M $1.918M $2.786M
YoY Change -31.0% -31.16% 55.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $134.0K $137.0K $2.900M
YoY Change -95.4% -95.28% 380.13%
Total Long-Term Assets $15.75M $14.76M $11.30M
YoY Change 57.53% 30.59% 19.46%
TOTAL ASSETS
Total Short-Term Assets $69.00M $75.95M $77.40M
Total Long-Term Assets $15.75M $14.76M $11.30M
Total Assets $84.75M $90.70M $88.70M
YoY Change -5.49% 2.26% 46.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.568M $2.617M $2.500M
YoY Change -47.59% 4.68% 43.68%
Accrued Expenses $3.559M $3.406M $7.000M
YoY Change -48.25% -51.34% 511.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.323M $11.41M $16.60M
YoY Change -50.08% -31.26% 37.3%
LONG-TERM LIABILITIES
Long-Term Debt $9.913M $9.861M $0.00
YoY Change
Other Long-Term Liabilities $6.757M $4.759M $2.400M
YoY Change 7492.13% 98.29% -27.27%
Total Long-Term Liabilities $9.913M $9.861M $2.400M
YoY Change 11038.2% 310.88% -27.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.323M $11.41M $16.60M
Total Long-Term Liabilities $9.913M $9.861M $2.400M
Total Liabilities $24.99M $26.03M $19.10M
YoY Change 49.11% 36.29% 23.92%
SHAREHOLDERS EQUITY
Retained Earnings -$224.9M -$211.7M
YoY Change
Common Stock $284.7M $276.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $59.76M $64.67M $69.67M
YoY Change
Total Liabilities & Shareholders Equity $84.75M $90.70M $88.70M
YoY Change -5.49% 2.26% 46.25%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$13.21M -$14.26M -$12.51M
YoY Change 28.49% 13.99% -2.44%
Depreciation, Depletion And Amortization $212.0K $220.0K $218.0K
YoY Change -8.23% 0.92% 12.37%
Cash From Operating Activities -$12.85M -$11.57M -$11.80M
YoY Change 31.57% -1.88% 7.78%
INVESTING ACTIVITIES
Capital Expenditures -$65.00K $27.00K $648.0K
YoY Change -74.0% -95.83%
Acquisitions
YoY Change
Other Investing Activities $3.000K $0.00 $10.00M
YoY Change -84.21% -100.0% -200.5%
Cash From Investing Activities -$62.00K -$27.00K $9.352M
YoY Change -73.16% -100.29% -193.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $191.0K $85.00K
YoY Change 124.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.11M 15.16M 834.0K
YoY Change 4.11% 1717.27% 2216.67%
NET CHANGE
Cash From Operating Activities -12.85M -11.57M -11.80M
Cash From Investing Activities -62.00K -27.00K 9.352M
Cash From Financing Activities 11.11M 15.16M 834.0K
Net Change In Cash -1.801M 3.556M -1.609M
YoY Change -367.21% -321.01% -92.29%
FREE CASH FLOW
Cash From Operating Activities -$12.85M -$11.57M -$11.80M
Capital Expenditures -$65.00K $27.00K $648.0K
Free Cash Flow -$12.78M -$11.60M -$12.44M
YoY Change 34.35% -6.77% 13.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001645460
CY2022Q1 cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
CY2021Q1 cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 cue Unsettled Cash Receivable From Sale Of Common Stock
UnsettledCashReceivableFromSaleOfCommonStock
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 cue Operating Lease Modification
OperatingLeaseModification
CY2021Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
CY2022Q1 cue Common Stock Warrants Exercisable Intrinsic Value
CommonStockWarrantsExercisableIntrinsicValue
3416000
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38327
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Cue Biopharma, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3324577
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
40 Guest Street
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
CY2022Q1 dei City Area Code
CityAreaCode
617
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
949-2680
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
CUE
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35372194
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67927000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64371000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
925000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3143000
CY2022Q1 cue Proceeds From Sale Of Common Stock
ProceedsFromSaleOfCommonStock
5127000
CY2021Q4 cue Proceeds From Sale Of Common Stock
ProceedsFromSaleOfCommonStock
0
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1968000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
955000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
75947000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
68469000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1918000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2112000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9884000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9810000
CY2022Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2668000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2721000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
137000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140000
CY2022Q1 us-gaap Assets
Assets
90704000
CY2021Q4 us-gaap Assets
Assets
83401000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2617000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2591000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3406000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4620000
CY2021Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
645000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5388000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4932000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11411000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12788000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4759000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5121000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9861000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q1 us-gaap Liabilities
Liabilities
26031000
CY2021Q4 us-gaap Liabilities
Liabilities
17909000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34174800
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34174800
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32202496
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32202496
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
34000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
276340000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
262906000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-211701000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197446000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
64673000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
90704000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83401000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1553000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5156000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4255000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10082000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9816000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
15238000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
14071000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14238000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12518000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
13000
CY2022Q1 us-gaap Interest Expense
InterestExpense
25000
CY2021Q1 us-gaap Interest Expense
InterestExpense
0
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14255000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12505000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14255000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12512000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32636383
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30434525
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
78911000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2436000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
919000
CY2021Q1 us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
85000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-7000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12505000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
69669000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10616000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3011000
CY2022Q1 cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-191000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14255000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
64673000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-14255000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-12505000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
303000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
318000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3011000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2436000
CY2022Q1 cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
-74000
CY2021Q1 cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
1118000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-5000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3000
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2218000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1093000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1590000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-250000
CY2022Q1 cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
53000
CY2021Q1 cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
-2000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
26000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
203000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1215000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-811000
CY2022Q1 cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-645000
CY2021Q1 cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-139000
CY2022Q1 cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
95000
CY2021Q1 cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1072000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11573000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11795000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
648000
CY2021Q1 cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-10000000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9352000
CY2022Q1 cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
5489000
CY2022Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
919000
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
142000
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
191000
CY2021Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
85000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15156000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
834000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3556000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1609000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64521000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
75016000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68077000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73407000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
21000
CY2022Q1 cue Operating Lease Modification
OperatingLeaseModification
1263000
CY2022Q1 cue Unsettled Cash Receivable From Sale Of Common Stock
UnsettledCashReceivableFromSaleOfCommonStock
5127000
CY2022Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-12-31
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67927000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p>
CY2022Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7221051
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6804062
CY2022Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
52445000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
52509000
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
52445000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
52509000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5582000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5556000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3664000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3444000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1918000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2112000
CY2022Q1 us-gaap Depreciation
Depreciation
220000
CY2021Q1 us-gaap Depreciation
Depreciation
218000
CY2022Q1 cue Amortization Of Trademark
AmortizationOfTrademark
3000
CY2022Q1 cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
80000
CY2021Q1 cue Amortization Of Trademark
AmortizationOfTrademark
3000
CY2021Q1 cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
97000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2023Q1 cue Prepayment Premium Rate
PrepaymentPremiumRate
0.0300
CY2024Q1 cue Prepayment Premium Rate
PrepaymentPremiumRate
0.0200
CY2025Q1 cue Prepayment Premium Rate
PrepaymentPremiumRate
0.0100
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
139000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
9861000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2000000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
4000000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4000000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0153
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0256
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1940000
CY2022Q1 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
3.86
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2022Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
142000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.921
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.957
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0061
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0118
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.922
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.947
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5654168
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y5M23D
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.06
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
107753
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.11
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6362415
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.62
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3904410
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.75
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10M17D
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
18531000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
816000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.26
CY2022Q1 cue Number Of Tranches
NumberOfTranches
2
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3011000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2436000
CY2022Q1 cue Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Of Common Stock
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueOfCommonStock
4.88
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
851969
CY2022Q1 cue Class Of Warrants Or Rights Cashless Issue Exercises
ClassOfWarrantsOrRightsCashlessIssueExercises
0
CY2022Q1 cue Class Of Warrant Or Right Number Of Securities Withheld
ClassOfWarrantOrRightNumberOfSecuritiesWithheld
0
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
851969
CY2022Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2500000
CY2022Q1 cue Milestone Payments Received
MilestonePaymentsReceived
2800000
us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
Upon execution of this lease agreement, the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and the other of which was applied to the first month’s rent. The Company also prepaid seven and one-half months’ rent pursuant to an amendment to the lease agreement executed on June 18, 2018. These amounts were recorded to deposits and prepaid expenses, respectively, at December 31, 2018
CY2022Q1 us-gaap Security Deposit Liability
SecurityDepositLiability
803000
CY2021Q4 us-gaap Security Deposit Liability
SecurityDepositLiability
803000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4030000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
5533000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1171000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10734000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
586000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
10148000
CY2022Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1338000
CY2021Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1220000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
95000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
145000
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.055
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y11M15D
CY2022Q1 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
13000
CY2022Q1 cue Non Cash Interest Expense Lease Liability
NonCashInterestExpenseLeaseLiability
43000

Files In Submission

Name View Source Status
0000950170-22-008990-index-headers.html Edgar Link pending
0000950170-22-008990-index.html Edgar Link pending
0000950170-22-008990.txt Edgar Link pending
0000950170-22-008990-xbrl.zip Edgar Link pending
cue-20220331.htm Edgar Link pending
cue-20220331.xsd Edgar Link pending
cue-20220331_cal.xml Edgar Link unprocessable
cue-20220331_def.xml Edgar Link unprocessable
cue-20220331_htm.xml Edgar Link completed
cue-20220331_lab.xml Edgar Link unprocessable
cue-20220331_pre.xml Edgar Link unprocessable
cue-ex10_3.htm Edgar Link pending
cue-ex31_1.htm Edgar Link pending
cue-ex31_2.htm Edgar Link pending
cue-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img76097529_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending